Does the media refer more to CBIO or NKTR?

In the previous week, Crescent Biopharma had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 4 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.64 beat Crescent Biopharma's score of 0.17 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or CBIO?

In the previous week, BioCryst Pharmaceuticals had 9 more articles in the media than Crescent Biopharma. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 6 mentions for Crescent Biopharma. BioCryst Pharmaceuticals' average media sentiment score of 1.18 beat Crescent Biopharma's score of 0.17 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, CBIO or CDNA?

CareDx has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 71.37 -$153.94M -$6.72 N/A CareDx $379.80M 6.62 -$21.35M $2.07 23.48

Does the media refer more to CBIO or CDNA?

In the previous week, CareDx had 9 more articles in the media than Crescent Biopharma. MarketBeat recorded 15 mentions for CareDx and 6 mentions for Crescent Biopharma. CareDx's average media sentiment score of 1.38 beat Crescent Biopharma's score of 0.17 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBIO or PHVS more profitable?

Pharvaris' return on equity of -61.40% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Pharvaris N/A -61.40% -56.00%

Does the media refer more to CBIO or PHVS?

In the previous week, Pharvaris had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 8 mentions for Pharvaris and 6 mentions for Crescent Biopharma. Pharvaris' average media sentiment score of 1.80 beat Crescent Biopharma's score of 0.17 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CBIO or VERA more profitable?

Vera Therapeutics' return on equity of -84.13% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -101.50% -86.86% Vera Therapeutics N/A -84.13% -66.79%

Does the media prefer CBIO or VERA?

In the previous week, Crescent Biopharma had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 2 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.64 beat Crescent Biopharma's score of 0.17 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Crescent Biopharma (CBIO) Competitors

$21.01 +2.47 (+13.30%)

As of 01:22 PM Eastern

Compare

CBIO vs. NKTR, BCRX, CDNA, PHVS, and VERA

Should you buy Crescent Biopharma stock or one of its competitors? Crescent Biopharma's main competitors and comparable companies include Nektar Therapeutics (NKTR), BioCryst Pharmaceuticals (BCRX), CareDx (CDNA), Pharvaris (PHVS), and Vera Therapeutics (VERA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Nektar Therapeutics?

Crescent Biopharma (NASDAQ:CBIO) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

In the previous week, Crescent Biopharma had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 4 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.64 beat Crescent Biopharma's score of 0.17 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	71.37	-$153.94M	-$6.72	N/A
Nektar Therapeutics	$54.59M	46.64	-$164.08M	-$6.70	N/A

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Crescent Biopharma presently has a consensus price target of $29.60, suggesting a potential upside of 42.10%. Nektar Therapeutics has a consensus price target of $141.50, suggesting a potential upside of 89.74%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Crescent Biopharma has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Summary

Crescent Biopharma beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Crescent Biopharma (NASDAQ:CBIO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 9 more articles in the media than Crescent Biopharma. MarketBeat recorded 15 mentions for BioCryst Pharmaceuticals and 6 mentions for Crescent Biopharma. BioCryst Pharmaceuticals' average media sentiment score of 1.18 beat Crescent Biopharma's score of 0.17 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals currently has a consensus price target of $20.60, indicating a potential upside of 104.67%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 42.10%. Given BioCryst Pharmaceuticals' higher probable upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Crescent Biopharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Crescent Biopharma	N/A	-101.50%	-86.86%

BioCryst Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.94	$263.86M	-$1.50	N/A
Crescent Biopharma	$10.84M	71.37	-$153.94M	-$6.72	N/A

Summary

BioCryst Pharmaceuticals beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to CareDx?

Crescent Biopharma (NASDAQ:CBIO) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

CareDx has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	71.37	-$153.94M	-$6.72	N/A
CareDx	$379.80M	6.62	-$21.35M	$2.07	23.48

In the previous week, CareDx had 9 more articles in the media than Crescent Biopharma. MarketBeat recorded 15 mentions for CareDx and 6 mentions for Crescent Biopharma. CareDx's average media sentiment score of 1.38 beat Crescent Biopharma's score of 0.17 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crescent Biopharma currently has a consensus price target of $29.60, suggesting a potential upside of 42.10%. CareDx has a consensus price target of $51.20, suggesting a potential upside of 5.34%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market.

CareDx has a net margin of 24.23% compared to Crescent Biopharma's net margin of 0.00%. CareDx's return on equity of 2.87% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
CareDx	24.23%	2.87%	2.17%

75.2% of Crescent Biopharma shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

CareDx beats Crescent Biopharma on 11 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Pharvaris?

Crescent Biopharma (NASDAQ:CBIO) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Crescent Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, meaning that its share price is 333% less volatile than the broader market.

Crescent Biopharma currently has a consensus price target of $29.60, suggesting a potential upside of 42.10%. Pharvaris has a consensus price target of $51.08, suggesting a potential upside of 44.41%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Pharvaris' return on equity of -61.40% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Pharvaris	N/A	-61.40%	-56.00%

Crescent Biopharma has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	71.37	-$153.94M	-$6.72	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 8 mentions for Pharvaris and 6 mentions for Crescent Biopharma. Pharvaris' average media sentiment score of 1.80 beat Crescent Biopharma's score of 0.17 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

75.2% of Crescent Biopharma shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pharvaris beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks.

How does Crescent Biopharma compare to Vera Therapeutics?

Crescent Biopharma (NASDAQ:CBIO) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Vera Therapeutics' return on equity of -84.13% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Vera Therapeutics	N/A	-84.13%	-66.79%

In the previous week, Crescent Biopharma had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Crescent Biopharma and 2 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.64 beat Crescent Biopharma's score of 0.17 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Crescent Biopharma has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	71.37	-$153.94M	-$6.72	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Crescent Biopharma presently has a consensus price target of $29.60, indicating a potential upside of 42.10%. Vera Therapeutics has a consensus price target of $81.15, indicating a potential upside of 127.29%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Vera Therapeutics beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$788.85M	$4.02B	$7.26B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-3.16	12.52	273.79	25.41
Price / Sales	71.37	1,362.92	676.44	124.05
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	4.86	16.29	12.87	6.16
Net Income	-$153.94M	-$22.72M	$3.48B	$349.24M
7 Day Performance	17.29%	-1.41%	-0.27%	-1.43%
1 Month Performance	40.08%	11.10%	6.56%	2.51%
1 Year Performance	57.45%	53.69%	25.23%	15.93%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	2.7351 of 5 stars	$21.01 +13.3%	$29.60 +40.9%	+35.5%	$785.92M	$10.84M	N/A	50	News Coverage
NKTR Nektar Therapeutics	2.5013 of 5 stars	$74.96 +1.7%	$141.50 +88.8%	+150.1%	$2.52B	$55.23M	N/A	220
BCRX BioCryst Pharmaceuticals	3.0817 of 5 stars	$9.83 +1.5%	$20.60 +109.6%	+22.7%	$2.47B	$940.61M	N/A	530	Positive News
CDNA CareDx	3.6711 of 5 stars	$50.80 +6.9%	$47.75 -6.0%	+258.1%	$2.46B	$379.80M	24.54	740	Positive News Analyst Forecast
PHVS Pharvaris	4.0216 of 5 stars	$37.23 -0.2%	$51.08 +37.2%	+56.3%	$2.44B	N/A	N/A	30	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. NKTR, BCRX, CDNA, PHVS, and VERA

How does Crescent Biopharma compare to Nektar Therapeutics?

Summary

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

Summary

How does Crescent Biopharma compare to CareDx?

Summary

How does Crescent Biopharma compare to Pharvaris?

Summary

How does Crescent Biopharma compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. NKTR, BCRX, CDNA, PHVS, and VERA

How does Crescent Biopharma compare to Nektar Therapeutics?

Does the media refer more to CBIO or NKTR?

Which has stronger valuation & earnings, CBIO or NKTR?

Do institutionals & insiders hold more shares of CBIO or NKTR?

Do analysts prefer CBIO or NKTR?

Is CBIO or NKTR more profitable?

Which has more risk and volatility, CBIO or NKTR?

Summary

How does Crescent Biopharma compare to BioCryst Pharmaceuticals?

Which has more volatility & risk, BCRX or CBIO?

Do insiders & institutionals believe in BCRX or CBIO?

Does the media prefer BCRX or CBIO?

Do analysts rate BCRX or CBIO?

Is BCRX or CBIO more profitable?

Which has higher valuation & earnings, BCRX or CBIO?

Summary

How does Crescent Biopharma compare to CareDx?

Which has higher valuation & earnings, CBIO or CDNA?

Does the media refer more to CBIO or CDNA?

Do analysts prefer CBIO or CDNA?

Which has more risk and volatility, CBIO or CDNA?

Is CBIO or CDNA more profitable?

Do institutionals & insiders hold more shares of CBIO or CDNA?

Summary

How does Crescent Biopharma compare to Pharvaris?

Which has more risk and volatility, CBIO or PHVS?

Do analysts rate CBIO or PHVS?

Is CBIO or PHVS more profitable?

Which has higher earnings & valuation, CBIO or PHVS?

Does the media refer more to CBIO or PHVS?

Do insiders & institutionals believe in CBIO or PHVS?

Summary

How does Crescent Biopharma compare to Vera Therapeutics?

Is CBIO or VERA more profitable?

Does the media prefer CBIO or VERA?

Do institutionals and insiders have more ownership in CBIO or VERA?

Which has higher earnings and valuation, CBIO or VERA?

Which has more volatility and risk, CBIO or VERA?

Do analysts recommend CBIO or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools